A UNSW Sydney-led team of scientists has made an advance that could eventually lead to a cure for sickle cell anaemia and other blood disorders.
By introducing a beneficial natural mutation into blood cells using the gene-editing technique CRISPR, a UNSW Sydney-led team of scientists has been able to switch on production of foetal haemoglobin – an advance that could eventually lead to a cure for sickle cell anaemia and other blood disorders.
People with thalassaemia or sickle cell anaemia have damaged adult haemoglobin – the vital molecule that picks up oxygen in the lungs and transports it around the body – and they require life-long treatment with blood transfusions and medication.
However, people with these diseases who also carry the beneficial natural mutation – known as British-198 – have reduced symptoms, because the mutation switches on the foetal haemoglobin gene that is normally turned off after birth.
The extra foetal haemoglobin in their blood, which has a very strong affinity for oxygen, does the work of the defective adult haemoglobin.
“With CRISPR gene-editing we can now precisely cut and alter single genes within our vast genome,” says study senior author and UNSW molecular biologist Professor Merlin Crossley.
“Our laboratory has shown that introducing the beneficial mutation British-198 into blood cells using this technology substantially boosts their production of foetal haemoglobin.
“Because this mutation already exists in nature and is benign, this ‘organic gene therapy’ approach should be effective and safe to use to treat, and possibly cure serious blood disorders. However, more research is still needed before it can be tested in people,” he says.
The study by scientists from UNSW, the Japanese Red Cross Society and the RIKEN BioResource Centre in Japan, is published in the journal Blood.
The beneficial British-198 mutation, which was first identified in a large British family in 1974, involves a change in just a single letter of the genetic code.
Carriers of this mutation have foetal haemoglobins levels as high as 20% of total haemoglobin, while most people’s foetal haemoglobin levels fall to about 1% of total haemoglobin after birth.
The researchers also discovered how this British-198 mutation works. They found it creates a new binding site for a protein called KLF1 that turns blood genes on.
Mutations affecting adult haemoglobin production are among the most common of all genetic variations, with about 5% of the world’s population carrying a defective gene.
“To turn the new gene editing approach into a therapy for blood disorders, the British-198 mutation would have to be introduced into blood-forming stem cells from the patient,” says Professor Crossley.
“A large number of stem cells would have to be edited in order to repopulate the patients’ blood with genetically enhanced cells.”
The Latest on: Genome therapy
- Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia on June 20, 2019 at 2:32 am
We identify regulators of enhancer formation as key mediators of the resistant state and show that non-genetic therapy resistance can be overcome by switching the enhancer dependencies of key genes ... […]
- The Prickly Debate on Germline Gene Therapy, and Moving It Forward on June 19, 2019 at 7:00 am
Rather than changing genes in a grown adult, germline gene therapy hopes to nip inheritable diseases at the earliest stages of conception. By editing the genetic makeup of the egg, sperm, or ... […]
- Gene therapy company Stoke Therapeutics draws strong interest for its IPO (STOK) on June 19, 2019 at 6:06 am
Within the healthcare sector, the gene therapy space has been mixed recently in terms of ... STOK believes it is pioneering a new way to treat the underlying causes of severe genetic diseases by ... […]
- The Next Boston? Cell And Gene Therapy Spark A Philly Building Boom on June 18, 2019 at 4:09 pm
In December 2017, the Food and Drug Administration approved the first-ever gene therapy process for treating a genetic condition. The applicant: Spark Therapeutics, a startup founded in 2013 by ... […]
- Probably Genetic helps families identify genetic conditions early with AI and DNA tests on June 18, 2019 at 1:24 pm
Probably Genetic hopes to provide families of children on the spectrum with more complete and correct diagnoses and a path to appropriate treatment and therapy. “There is really low awareness ... […]
- Groundbreaking Gene Therapy Now at Goryeb Children's Hospital on June 18, 2019 at 8:53 am
Using gene therapy, DNA containing a properly functioning ... Atlantic Health System has been at the forefront of genetic disorders research and treatment, offering clinical trials for a multitude ... […]
- Cell and Gene Therapy Market 2019 | Rich Product Pipeline Develop Rapidly on June 18, 2019 at 6:13 am
Jun 18, 2019 (News AIM via COMTEX) -- North America holds dominant position in the global cell and gene therapy market, owing to high prevalence of genetic disorders. According to the U.S. Pharmacist ... […]
- Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous? on June 15, 2019 at 2:18 pm
Here's how Zynteglo may transform the treatment of this genetic disorder ... the European approval of bluebird bio's Zynteglo. A gene therapy, Zynteglo inserts a functional copy of a modified ... […]
- Bluebird Bio CEO defends $1.8 million price for gene therapy — 'It's really thinking about it differently' on June 14, 2019 at 5:50 pm
Bluebird Bio CEO Nick Leschly defends the biotech company's $1.8 million price tag for its new gene therapy to treat a rare genetic blood disorder. He says the one-time treatment is a game changer for ... […]
- Bluebird prices gene therapy at 1.575 million euros over five years on June 14, 2019 at 5:07 am
(Reuters) - Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to ... […]
via Google News and Bing News